Aclarion Inc. Common Stock (ACON)
Stock · NASDAQ · Health Care
$1.85as of 10/16/2026
Price chart
ACON Signal Track Record
How signals performed across all stocks →What ACON's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakout | 20 | -16.1% | 10% | September 23, 2026 |
| Volume Spike | 19 | -9.5% | 26% | September 10, 2026 |
| Bollinger Band BreakdownActive now | 15 | -11.0% | 27% | July 27, 2026 |
| Any 20-session window (baseline) | -9.5% | 29% |
Computed by MarketWall from daily closing prices since February 7, 2023. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ACON
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software…
- Sector
- Health Care
- Industry
- Medical Specialities
- Employees
- 10
- Website
- aclarion.com/
Fundamentals
- 1-day range
- $1.85$1.94
- Market cap
- $5.79M
- P/E (trailing)
- —
- P/E (forward)
- -0.34
- EPS (trailing)
- $-7.92
- Dividend yield
- —
- Beta
- 1.25
- Avg. volume
- 51.8K
Forecasts
2 analyst ratings
Aclarion Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ACONAclarion Inc. Common Stock$1.85▼ 5.27%Market cap $5.79MP/E —$1.89$9.38
- BGLCBioNexus Gene Lab Corp Common stock$1.2▼ 1.64%Market cap $3.82MP/E —$1.07$5.89
- AMSAmerican Shared Hospital Services Common Stock$1.28▲ 1.59%Market cap $9.67MP/E —$1.21$2.39
- ADVBAdvanced Biomed Inc. Common Stock$3.98▼ 18.44%Market cap $12.29MP/E 1.53$3.61$24.23
- YDESWYD Bio Limited Warrants$0.599▼ 9.24%Market cap $16.29MP/E —$0.1904$2.5
- MDXHMDxHealth SA Ordinary Shares$0.207▼ 65.73%Market cap $22.50MP/E —$0.4$5.33
- SERASera Prognostics Inc. Class A Common Stock$2.06▲ 1.48%Market cap $78.32MP/E —$1.56$3.95
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ACON Aclarion Inc. Common Stock | $5.79M | — | $1.85 | ▼ 5.27% | $1.89$9.38 |
| BGLC BioNexus Gene Lab Corp Common stock | $3.82M | — | $1.2 | ▼ 1.64% | $1.07$5.89 |
| AMS American Shared Hospital Services Common Stock | $9.67M | — | $1.28 | ▲ 1.59% | $1.21$2.39 |
| ADVB Advanced Biomed Inc. Common Stock | $12.29M | 1.53 | $3.98 | ▼ 18.44% | $3.61$24.23 |
| YDESW YD Bio Limited Warrants | $16.29M | — | $0.599 | ▼ 9.24% | $0.1904$2.5 |
| MDXH MDxHealth SA Ordinary Shares | $22.50M | — | $0.207 | ▼ 65.73% | $0.4$5.33 |
| SERA Sera Prognostics Inc. Class A Common Stock | $78.32M | — | $2.06 | ▲ 1.48% | $1.56$3.95 |
P/E shows — for peers not currently carrying a live signal of their own.
Institutional Ownership
March 31, 2026
- Total shares held
- 112.6K
- Total value held
- $368.1K
- Institutional holders
- 10
- Unknown34.9K
- Unknown31.2K
- Unknown14.6K
- Unknown10.0K
- Unknown9.6K
- Unknown6.8K
- Unknown5.4K
- Unknown3
- Unknown1
- Unknown1
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
ACON Adds NYU Langone Health to CLARITY Trial Network
Aclarion Inc. announced that NYU Langone Health has joined its CLARITY Trial Network. The partnership brings the health system into 11 enrolling sites, expanding the company’s clinical trial footprint. This move could increase the pace of data collection for Aclarion’s pipeline. The announcement comes as the stock trades near its 14‑day support level.
ACON Adds NYU Langone Health to CLARITY Trial Network. Aclarion Inc. announced that NYU Langone Health has joined its CLARITY Trial Network. The partnership brings the health system into 11 enrolling sites, expanding the company’s clinical trial footprint. This move could increase the pace of data collection for Aclarion’s pipeline. The announcement comes as the stock trades near its 14‑day support level.